TriangleNCT02981368 · CITED IN SOURCE DOCUMENTS
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE2, PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2021-08-09
This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy (Cohort A) or in patients with locally recurrent or metastatic disease willing to undergo biopsy (Cohort B). Cohort B is complete and no longer recruiting subjects.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Specificity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A)
Sensitivity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A)
Shift From Baseline in Selected Hematology Laboratory Values at Follow-up (Safety Outcome Measure)
Shift From Baseline in Selected Clinical Chemistry Laboratory Values at Follow-up (Safety Outcome Measure)
Changes From Baseline in Electrocardiogram (ECG) Parameters (Safety Outcome Measure)
Mean Changes From Baseline in Blood Pressure Post 18F-DCFPyL Dosing (Safety Outcome Measure)
Mean Change From Baseline in Heart Rate Post 18F-DCFPyL Dosing (Safety Outcome Measure)
Mean Change From Baseline in Respiration Rate Post 18F-DCFPyL Dosing (Safety Outcome Measure)
Mean Change From Baseline in Temperature Post 18F-DCFPyL Dosing (Safety Outcome Measure)
Sensitivity of 18F-DCFPyL PET/CT Imaging to Detect Prostate Cancer Within Sites of Metastasis or Local Recurrence Relative to Histopathology in Participants With Recurrent or Metastatic Prostate Cancer (Cohort B)
Comparison of Detection Rates for Lesion Counts By Location and Overall Between 18F-DCFPyL PET/CT and Conventional Imaging
Positive Predictive Value (PPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Prostate Gland of High Risk Prostate Cancer Participants (Cohort A)
Negative Predictive Value (NPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Prostate Gland of High Risk Prostate Cancer Participants (Cohort A)
Positive Predictive Value (PPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Lymph Nodes of High Risk Prostate Cancer Participants (Cohort A)
Negative Predictive Value (NPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Lymph Nodes of High Risk Prostate Cancer Participants (Cohort A)
Positive Predictive Value (PPV) of 18F-DCFPyL PET/CT Imaging to Predict Prostate Cancer Within Sites of Local Recurrence and Other Metastatic Lesions in Participants With Recurrent or Metastatic Prostate Cancer (Cohort B)
Peak Plasma Concentration (Cmax) of 18F-DCFPyL in a Subset of Participants
Area Under the Plasma Concentration Versus Time Curve (AUC) of 18F-DCFPyL in a Subset of Participants
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: 1. Histologically confirmed adenocarcinoma of the prostate. 2. Subjects provide signed informed consent and confirm that they are able and willing to comply with all protocol requirements. Cohort A Only: * At least high risk prostate cancer defined by NCCN Guidelines Version 3.2016 (clinical stage ≥T3a or PSA \>20 ng/mL or Gleason score ≥8). * Scheduled or planned radical prostatectomy with PLND. Cohort B Only: \[Enrollment is complete; No longer recruiting subjects\] * Radiologic evidence of local recurrence or new or progressive metastatic disease demonstrated on anatomical imaging (CT, MRI, or ultrasound), whole-body bone scan (99m-Tc-MDP or Na-18F) within 4 weeks of enrollment. * If prior treatment with radiation or ablative therapy, evidence of recurrence outside the confines of prior treated site(s) is needed. * Scheduled or planned percutaneous biopsy of at least one amenable lesion. Exclusion Criteria: 1. Subjects administered any high energy (\>300 KeV) gamma-emitting radioisotope within five physical half-lives, or any IV iodinated contrast medium within 24 hours, or any high density oral contrast medium (oral water contrast is acceptable) within 5 days, prior to study drug injection. 2. Subjects with any medical condition or other circumstance that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion. Cohort A Only: * Patients with prior androgen deprivation therapy or any investigational neoadjuvant agent or intervention Cohort B Only: \[Enrollment is Complete; No longer recruiting subjects\] * Prior radiation or ablative therapy to intended site of biopsy, if within the prostate bed * Initiation of new therapy for recurrent and/or progressive metastatic disease since radiographic documentation of recurrence/progression.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- MALE
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
- intervention Names
- Drug: 18F-DCFPyL Injection
- Diagnostic Test: PET/CT imaging
- label
- 18F-DCFPyL Injection
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- 18F-DCFPyL Injection
- description
- A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
- name
- 18F-DCFPyL Injection
- other Names
- PyL
- type
- DRUG
- arm Group Labels
- 18F-DCFPyL Injection
- description
- PET/CT imaging will be acquired 1-2 hours post-PyL injection
- name
- PET/CT imaging
- type
- DIAGNOSTIC_TEST
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- DIAGNOSTIC
Enrollment
- count
- 385
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- The primary analysis in Cohort A will test the co-primary endpoints of sensitivity and specificity of 18F-DCFPyL PET/CT imaging relative to histopathology for metastatic disease in pre-prostatectomy patients. For each co-primary endpoint there will be three independent imaging readers. At least two of the three readers must reject the null hypothesis for specificity to be deemed a success. If specificity is a success, then the same two readers need to reject the null hypothesis for sensitivity to reach overall success of the primary endpoint.
- measure
- Specificity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A)
- time Frame
- Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
- description
- The primary analysis in Cohort A will test the co-primary endpoints of sensitivity and specificity of 18F-DCFPyL PET/CT imaging relative to histopathology for metastatic disease in pre-prostatectomy patients. For each co-primary endpoint there will be three independent imaging readers. At least two of the three readers must reject the null hypothesis for specificity to be deemed a success. If specificity is a success, then the same two readers need to reject the null hypothesis for sensitivity to reach overall success of the primary endpoint.
- measure
- Sensitivity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A)
- time Frame
- Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
- secondary Outcomes
- description
- Shifts from baseline to worst post-baseline visit for hematology laboratory values for all participants included in the Safety Set. The Safety Set includes all participants who received any amount of 18F-DCFPyL. Data are presented for participants in Cohort A and Cohort B.
- measure
- Shift From Baseline in Selected Hematology Laboratory Values at Follow-up (Safety Outcome Measure)
- time Frame
- From time of screening (baseline) until pre-surgery/biopsy (within 28 days post-study drug dosing).
- description
- Shifts from baseline to worst post-baseline visit for clinical chemistry laboratory values for all participants included in the Safety Set. The Safety Set includes all participants who received any amount of 18F-DCFPyL. Data are presented for participants in Cohort A and Cohort B.
- measure
- Shift From Baseline in Selected Clinical Chemistry Laboratory Values at Follow-up (Safety Outcome Measure)
- time Frame
- From time of screening (baseline) until pre-surgery/biopsy (within 28 days post-study drug dosing).
- measure
- Changes From Baseline in Electrocardiogram (ECG) Parameters (Safety Outcome Measure)
- time Frame
- Changes in ECG pre-drug dosing and within 1-2 hours post-dosing
- measure
- Mean Changes From Baseline in Blood Pressure Post 18F-DCFPyL Dosing (Safety Outcome Measure)
- time Frame
- Measured at two intervals on the day of dosing, pre-dosing (baseline) and post-dosing/pre-imaging.
- measure
- Mean Change From Baseline in Heart Rate Post 18F-DCFPyL Dosing (Safety Outcome Measure)
- time Frame
- Measured at two intervals on the day of dosing, pre-dosing (baseline) and post-dosing/pre-imaging.
- measure
- Mean Change From Baseline in Respiration Rate Post 18F-DCFPyL Dosing (Safety Outcome Measure)
- time Frame
- Measured at two intervals on the day of dosing, pre-dosing (baseline) and post-dosing/pre-imaging.
- measure
- Mean Change From Baseline in Temperature Post 18F-DCFPyL Dosing (Safety Outcome Measure)
- time Frame
- Measured at two intervals on the day of dosing, pre-dosing (baseline) and post-dosing/pre-imaging.
- description
- Sensitivity (True Positive rate) measures the proportion of positives that are correctly identified (i.e., the proportion of those who have some condition (affected) who are correctly identified as having the condition).
- measure
- Sensitivity of 18F-DCFPyL PET/CT Imaging to Detect Prostate Cancer Within Sites of Metastasis or Local Recurrence Relative to Histopathology in Participants With Recurrent or Metastatic Prostate Cancer (Cohort B)
- time Frame
- Within 28 days of 18F-DCFPyL PET/CT imaging, conventional image-guided biopsy occurred.
- description
- The number of lesions detected on imaging categorized as bone, visceral/soft tissue, lymph nodes, and the prostate gland will be determined by each of the central imaging core lab independent readers. The sum of lesions per participant per tissue type and overall will be computed for each participant based on each reader's lesion count. This will be calculated from the 18F-DCFPyL PET/CT scan results as well as the conventional imaging results.
- measure
- Comparison of Detection Rates for Lesion Counts By Location and Overall Between 18F-DCFPyL PET/CT and Conventional Imaging
- time Frame
- Within 1-2 hours of 18F-DCFPyL dosing, a whole body PET/CT scan will be taken
- description
- Positive Predictive Value (PPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The PPV is determined from the number of true positives (positive 18F-DCFPyL image and a positive histopathology result for prostate cancer) divided by the number of participants with a positive 18F-DCFPyL image.
- measure
- Positive Predictive Value (PPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Prostate Gland of High Risk Prostate Cancer Participants (Cohort A)
- time Frame
- Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
- description
- Negative Predictive Value (NPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The NPV is determined from the number of true negatives (negative 18F-DCFPyL image and a negative histopathology result for prostate cancer) divided by the number of participants with a negative 18F-DCFPyL image.
- measure
- Negative Predictive Value (NPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Prostate Gland of High Risk Prostate Cancer Participants (Cohort A)
- time Frame
- Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
- description
- Positive Predictive Value (PPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The PPV is determined from the number of true positives (positive 18F-DCFPyL image and a positive histopathology result for prostate cancer) divided by the number of participants with a positive 18F-DCFPyL image.
- measure
- Positive Predictive Value (PPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Lymph Nodes of High Risk Prostate Cancer Participants (Cohort A)
- time Frame
- Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
Full study description
- brief Summary
- This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy (Cohort A) or in patients with locally recurrent or metastatic disease willing to undergo biopsy (Cohort B). Cohort B is complete and no longer recruiting subjects.
Source references
- references
- citation
- Saperstein L, Rowe SP, Gorin MA, Pienta KJ, Siegel BA, Morris MJ, Baskaran S, Stambler N, DiPippo VA, Denes BS. Impact of Concomitant Hormone Therapy on the Diagnostic Performance of 18F-Piflufolastat PET/CT in Prostate Cancer Patients: A Sub-Group Analysis of OSPREY Cohort B. Prostate. 2025 Aug;85(11):1005-1015. doi: 10.1002/pros.24909. Epub 2025 May 4.
- pmid
- 40320701
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-11c94d17a9e24cf287e0
- requested nct id
- NCT02981368
- primary nct id
- NCT02981368
- source kind
- fda_spl_label
- source record id
- 558f7e93-a905-767a-e063-6294a90a1527
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 86e1432d724a62158c374951caea72e2e3c747d895ac4d7d3b2847b4ad97ea15
- payload
- application numbers
- NDA220089
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-11c94d17a9e24cf287e0
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02981368
- occurrences
- context exact
- based on data from two prospective, open-label, multi-center clinical studies of another formulation of piflufolastat F 18 in men with prostate cancer: OSPREY (NCT02981368) and CONDOR (NCT03739684). The results of these two studies are presented below. OSPREY OSPREY enrolled a cohort of 268 men with biopsy-proven prostate cancer
- end
- 260
- exact text
- NCT02981368
- start
- 249
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/55/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 558f7e93-a905-767a-e063-6294a90a1527
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 75b7617538408880c08714b72038f16c454f10f371171c6b22ebb55a19dbef93
- spl effective time
- 20260701
- spl set id
- 121c1cb8-6f60-4644-a775-b81c6f21d812
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-bbc7744f3b3ce08ee15f
- requested nct id
- NCT02981368
- primary nct id
- NCT02981368
- source kind
- fda_spl_label
- source record id
- db2acb00-3e3b-4ecc-b532-08e456075404
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- payload sha256
- 2e33e45f249f80ec66484aace3490d93a561d13e0dc45ebc63a76af260ae8855
- payload
- application numbers
- NDA214793
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-bbc7744f3b3ce08ee15f
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02981368
- occurrences
- context exact
- L STUDIES The safety and efficacy of PYLARIFY were evaluated in two prospective, open-label, multi-center clinical studies in men with prostate cancer: OSPREY (NCT02981368) and CONDOR (NCT03739684). OSPREY OSPREY enrolled a cohort of 268 men with biopsy-proven prostate cancer who were considered candidates for radical prostatecto
- end
- 181
- exact text
- NCT02981368
- start
- 170
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00700.json
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source json pointer
- /results/23/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- db2acb00-3e3b-4ecc-b532-08e456075404
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- e45d590a778b152334dad5711f48c1cd04211cd8016916190739af57fcf42fcf
- spl effective time
- 20260218
- spl set id
- a00e5cbc-4fd5-4280-82ec-cd3498df4553
Preserved source evidence · Not medical advice